Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody
Light Chain Bioscience is very excited to announce that our manuscript describing the development and characterization of NILK-2401, a CD47/CEACAM5 bispecific antibody, has been published in Frontiers in Immunology.i
NILK-2401 is a bispecific antibody that drives selective and effective CD47 blockade to tumor cells expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5, CEA) by pairing a high affinity anti-CEA targeting arm to an anti-CD47 arm of optimized low affinity. As such, CD47 blockade is selective to CEA-bearing cells, thus avoiding unwanted CD47 blockade on other cell types (e.g., red blood cells and platelets). Due to its selectivity, the molecule contains a fully competent IgG1 Fc-domain allowing ADCC and ADCP effector functions. Building upon ongoing clinical trial investigating NI-1801 (our CD47/Mesothelin bispecific antibody) in patients with solid cancers, Light Chain Bioscience proudly assumes the role of clinical development sponsor in collaboration with partner LamKap Bio beta AG. We are delighted to announce the submission of a Clinical Trial Application (CTA) in Europe, marking a significant milestone in our commitment to advancing novel cancer therapies.
↠ Read: Full article
Front. Immunol., 24 April 2024
